Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanofi (SNY) Cash & Equivalents (2016 - 2026)

Sanofi's Cash & Equivalents history spans 18 years, with the latest figure at $6.9 billion for Q1 2026.

  • On a quarterly basis, Cash & Equivalents fell 11.44% to $6.9 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $6.9 billion, a 11.44% decrease, with the full-year FY2025 number at $8.9 billion, up 12.09% from a year prior.
  • Cash & Equivalents hit $6.9 billion in Q1 2026 for Sanofi, down from $8.9 billion in the prior quarter.
  • Over the last five years, Cash & Equivalents for SNY hit a ceiling of $13.9 billion in Q2 2023 and a floor of $6.9 billion in Q1 2023.
  • Historically, Cash & Equivalents has averaged $9.2 billion across 5 years, with a median of $8.6 billion in 2025.
  • The widest YoY moves for Cash & Equivalents: up 28.71% in 2023, down 38.34% in 2023.
  • Tracing SNY's Cash & Equivalents over 5 years: stood at $13.0 billion in 2022, then decreased by 27.88% to $9.4 billion in 2023, then dropped by 15.15% to $8.0 billion in 2024, then increased by 12.09% to $8.9 billion in 2025, then decreased by 22.23% to $6.9 billion in 2026.
  • Business Quant data shows Cash & Equivalents for SNY at $6.9 billion in Q1 2026, $8.9 billion in Q4 2025, and $8.7 billion in Q3 2025.